- Home
- GLXG vs NRXS Comparison
GLXG vs NRXS Comparison
Compare GLXG & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLXG
- NRXS
- Stock Information
- Founded
- GLXG 2013
- NRXS 2011
- Country
- GLXG Hong Kong
- NRXS United States
- Employees
- GLXG N/A
- NRXS N/A
- Industry
- GLXG
- NRXS
- Sector
- GLXG
- NRXS
- Exchange
- GLXG NYSE
- NRXS Nasdaq
- Market Cap
- GLXG 11.1M
- NRXS 13.0M
- IPO Year
- GLXG 2024
- NRXS 2023
- Fundamental
- Price
- GLXG $0.55
- NRXS $2.49
- Analyst Decision
- GLXG
- NRXS Strong Buy
- Analyst Count
- GLXG 0
- NRXS 1
- Target Price
- GLXG N/A
- NRXS $7.00
- AVG Volume (30 Days)
- GLXG 174.0K
- NRXS 155.9K
- Earning Date
- GLXG 08-16-2025
- NRXS 08-08-2025
- Dividend Yield
- GLXG N/A
- NRXS N/A
- EPS Growth
- GLXG N/A
- NRXS N/A
- EPS
- GLXG N/A
- NRXS N/A
- Revenue
- GLXG $3,711,233.00
- NRXS $2,934,945.00
- Revenue This Year
- GLXG N/A
- NRXS $138,883.78
- Revenue Next Year
- GLXG N/A
- NRXS $118.59
- P/E Ratio
- GLXG N/A
- NRXS N/A
- Revenue Growth
- GLXG N/A
- NRXS 27.52
- 52 Week Low
- GLXG $0.39
- NRXS $1.33
- 52 Week High
- GLXG $16.93
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- GLXG N/A
- NRXS 49.91
- Support Level
- GLXG N/A
- NRXS $2.33
- Resistance Level
- GLXG N/A
- NRXS $2.67
- Average True Range (ATR)
- GLXG 0.00
- NRXS 0.17
- MACD
- GLXG 0.00
- NRXS -0.01
- Stochastic Oscillator
- GLXG 0.00
- NRXS 46.43
About GLXG GALAXY PAYROLL GROUP LTD
Galaxy Payroll Group Ltd provides payroll outsourcing, employment, consultancy, and market research services based in Hong Kong. Its client base includes retail, trading, industrial, IT, financial, and professional services industries. Geographically, the company derives maximum revenue from its clients in the People's Republic of China and the rest from Hong Kong, Macau, Taiwan, Japan, Thailand, Singapore, and other countries.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).